Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Uncategorized

Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 20, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City .